Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04870866 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 17, 2022 (before its estimated September 3, 2024 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Feb 3, 2022 to Sep 3, 2024 Completion date: Feb 16, 2027 to Jun 16, 2027v3 Show 1 more changeShow less
    • Completion date: Feb 16, 2027 to Jun 16, 2027
  2. Secondary endpoints: details revised at 2 of 9 entriesv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study investigates the effect of dietary supplementation of nicotinamide ribonucleoside (NR) in children with ataxia telangiectasia (AT), with main focus on neurological symptoms.
Trial Details
NCT Number NCT04870866
Lead Sponsor University Hospital, Akershus
Collaborators: The Bergesen Foundation, South-Eastern Norway Regional Health Authority, Sykehuset Innlandet HF, Oslo University Hospital, St. Olavs Hospital, Haukeland University Hospital, University Hospital of North Norway, University of Bergen
Conditions Ataxia Telangiectasia
Enrollment 13 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov